El boom in weight loss drugs like Ozempic and other GLP-1 agonists It has overwhelmed both healthcare systems and regulators. The shortage of official packaging is now compounded by a wave of counterfeit products, prepared irregularly or sold through websites and social media that masquerade as legitimate channels.
Amidst cross-warnings from within the pharmaceutical industry itself, notices of the European Medicines Agency (EMA) And with documented cases of serious health damage, the debate has moved to Brussels, to community pharmacies and, above all, to European consumers looking to lose weight quickly.
Ozempic and GLP-1 agonists: what they are and why there is so much demand
Ozempic, Wegovy, Mounjaro or Zepbound are drugs based on GLP-1 receptor analoguesThese drugs, initially designed to manage type 2 diabetes and, in some cases, also authorized for the treatment of obesity, work by regulating appetite and glucose levels, resulting in significant weight loss for many patients.
The media success of these injectable pens, combined with simplistic messages about “miracle weight loss injections”This has triggered a surge in global demand. In Europe, authorities have limited stocks to ensure access for people with diabetes, leading to a parallel market for purported “Ozempic” and very similar products.
This situation of Prolonged shortage and high expectations It is the perfect breeding ground for websites, social media profiles and so-called "online clinics" that promise cheaper versions, over-the-counter shipping or express results with hardly any medical controls.
Concern in Brussels: mixtures in pharmacies and unauthorized copies
The Danish pharmaceutical company Novo Nordisk, responsible for Ozempic and WegovyThe company has highlighted a sensitive aspect of the major overhaul of pharmaceutical legislation currently being negotiated in the European Union. According to the company, the new framework could allow certain pharmacies to manufacture compounded versions of these weight-loss medications on a larger scale than they currently can.
Under current regulations, the preparation of individualized medications in pharmacies is only permitted in very specific situationsCases of shortages, special dosage requirements (e.g., lower doses for children), or when there is no commercially available presentation that suits the patient. Novo Nordisk fears that the proposed wording relaxes these limits.
A company spokesperson warned that if the possibility of making compounded medications with GLP-1 analogues is expanded, Some pharmacies might start "stockpiling"That is, to prepare and store these mixes in advance, rather than making them only in response to a specific recipe. From their point of view, that would open the door to a “wild west” of unregulated products that would imitate Ozempic or Wegovy.
However, the Pharmaceutical Group of the European Union (PGEU)The association, which represents more than 400.000 community pharmacists, considers these warnings exaggerated. Its general secretary, Ilaria Passarini, maintains that there is no intention to allow mass production or the creation of copies of innovative medicines, and that community pharmacies are not requesting changes to expand their compounding capacity.
Meanwhile, member states and the European Parliament continue to negotiate the details of the so-called “pharmaceutical package,” with a view to reaching a political agreement in the coming months, in a climate of media pressure regarding the risks of fake Ozempic.
Explosion of the online market for counterfeit Ozempic-type medicines
Aside from the legislative debate, the warnings from health authorities focus particularly on the online marketplace for purported GLP-1 slimming drugsBoth the EMA and the US Food and Drug Administration (FDA) have detected a sharp increase in counterfeit products being sold as GLP-1 agonists.
These frauds include imitations of semaglutide, liraglutide or tirzepatideThese products, presented as "original" or "generic" alternatives to Ozempic, Wegovy, or Mounjaro, are marketed on professional-looking websites, online marketplaces, weight-loss forums, and, above all, through targeted ads on social media.
Authorities have verified that many of these pages use official logos, manipulated photographs, and false recommendations to lend credibility to the products. Sometimes, even certificates from European regulatory agencies are forged to make the user believe that the drug has been authorized.
In Europe, the regulations are clear: Online sales of prescription drugs are heavily restrictedAnd in countries like Spain, only legally authorized pharmacies can dispense them, and only under certain conditions. However, many of these accounts are managed from outside the EU, which complicates the closure and prosecution of these activities.
Outside of Europe, customs services in the United States have reported shipments of counterfeit Ozempic and Wegovy pens hidden in everyday objectsThey are sold as children's toys, which demonstrates the level of organization of these networks. The price difference compared to the legal product and the promise of obtaining it "without waiting and without a prescription" are the main draw.
Real health risks: from incorrect doses to toxic substances
Laboratories such as Eli Lilly, manufacturer of Mounjaro and ZepboundThey have been warning for months that the problem is not just economic or related to unfair competition. The main danger is health-related: many of these so-called GLP-1 drugs do not contain what they promise.
According to FDA investigations, counterfeit products can lack the active ingredientThey may include different substances, contain doses far higher or lower than the correct ones, or incorporate directly toxic compounds. Furthermore, they are often produced in facilities without quality controls, without sterility guarantees, and without the supervision of any regulatory body.
As of July 31, 2025, the FDA had collected hundreds of reports of adverse events associated with semaglutide and tirzepatide “combinations” In the United States, some of these cases required hospitalization. Documented cases include a patient who received a pen labeled Ozempic that actually contained insulin, and another who developed serious infections after using a product purchased online.
The EMA shares this assessment and emphasizes that these illegal preparations can lead to lack of therapeutic efficacy, severe adverse reactions, and dangerous interactions with other medications. Therefore, he insists that these treatments should only be used under medical supervision, with a prescription, and purchased from accredited pharmacies.
In an environment where aesthetic pressure and the urgency to lose weight prevail over prudence, specialists remind us that No drug is risk-freeand even less so when it is acquired through channels that circumvent any type of health control.
Generative AI and impersonation of healthcare organizations: the new face of fraud
The rise in counterfeit medications like Ozempic coincides with a rapid evolution in cybercriminals' own tactics. Investigations by the cybersecurity firm Check Point Software Technologies They have identified a new generation of pharmaceutical scams that combine the sale of illicit products with the intensive use of generative artificial intelligence.
Instead of simply reproducing a couple of misleading advertisements, some criminal networks build entire “ecosystems” around fake GLP-1 drugs: fabricated doctor profiles, fictitious clinical reports, AI-generated patient reviews, purported good manufacturing practice certificates, and payment websites that mimic trusted businesses.
These campaigns copy in great detail the visual identity of national health institutionssuch as corporate colors, fonts, uniforms, flags, logos, and regulatory seals. In European countries, imitations of health ministries, national health services, and even drug agencies have been identified, making it difficult for the average user to distinguish, at first glance, whether the website is real or not.
Most of these operations begin with AI-created “before and after” imagesThese scams showcase dramatic and seemingly believable weight loss. From this initial impact, the victim is led into an environment that simulates a complete medical experience: health questionnaires, chats with "specialists" who are actually bots, personalized recommendations, and finally, payment for the supposed treatment.
The big advantage for scammers is that generative AI allows adapt these campaigns to each country in a matter of minuteschanging doctors' names, institutional symbols, languages, or cultural details, and releasing new versions as soon as the previous ones are detected and deactivated.
Europe and Spain face the challenge of containing fraud
In the European context, the threat of Fake medicines like Ozempic intersect with other health debates: shortages, pressure on primary care, lack of resources for online inspection or regulatory differences between Member States.
Countries like Spain already have strict restrictions on the online sale of prescription drugs, but authorities acknowledge that Fraudulent ads and profiles operate primarily from outside the EUThis requires international cooperation. The EMA and national agencies are stepping up surveillance, strengthening border controls, and coordinating with law enforcement agencies to detect suspicious shipments.
At the same time, they are promoting Information campaigns aimed at healthcare professionals and the public, so that they can recognize warning signs: prices that are too low, promises of immediate results, the possibility of buying without a prescription, or the use of institutional seals that do not match the website where they appear.
The industry itself, from giants like Novo Nordisk to Eli Lilly, is developing authenticity verification tools of its products and collaborating with regulatory authorities and law enforcement agencies to pursue both the physical counterfeiting of medicines and the digital impersonation of its brands.
Even so, the speed at which fraudulent offers multiply on social media and search engines necessitates a constant effort to stay updated. Experts agree that Pressure on GLP-1 slimming treatments will continue at least until 2026as long as supply tensions persist and demand continues to grow.
How can patients protect themselves against fake Ozempic?
Regulatory agencies and experts reiterate that the first line of defense is the information from the patientAlthough scams are becoming increasingly sophisticated, there are a number of basic guidelines that significantly reduce the risk of falling victim to them.
In the case of Spain and the rest of the EU, the main recommendation is buy only at authorized pharmaciesWhether in person or, if permitted by law, through their official online platforms, any site offering prescription drugs without a prescription, at half price, or with shipping from foreign countries should raise immediate suspicion.
It is also convenient Be wary of ads on social media and forums They promise quick results, aggressive discounts, or unlimited availability of products that are supposedly out of stock. Many of these messages use timers, "limited stock" warnings, or exaggerated testimonials to push for impulsive decisions.
Another practical measure is Verify any alleged medical endorsement or regulatory sealIf a website claims to be supported by the EMA, a health ministry, or a scientific society, it is advisable to go directly to the official website of that organization and check if it is listed as a collaborator or authorized entity.
Finally, patients who are using or are about to start treatment with GLP-1 agonists should Always discuss any online offer with your doctor. that they find. The professional can help distinguish legitimate products from fake alternatives and, in case of suspicion, advise on how to report it to the competent authorities.
The surge in demand for GLP-1-based weight-loss drugs, combined with supply problems and the push from artificial intelligence, has created a scenario in which Counterfeit Ozempic-type medicines have become a very lucrative business for organized crime.Amid the regulatory gaps under discussion in Brussels, the rise of the online market, and sophisticated campaigns to impersonate health organizations, the role of authorities, pharmaceutical companies, and patients themselves will be key to preventing the search for a quick fix for being overweight from ending in a serious health risk.